Cancer Gene Therapy Clinical Trials. From the Bench to the Clinic

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter focuses on some of the most important considerations in the design of gene therapy trials. Gene therapy is a medical intervention based on the introduction of genetic material in human cells in vivo or in vitro. Preclinical studies in support of use of gene transfer vector in clinical studies should be conducted in compliance with the regulations for good laboratory practice. It is suggested that when determining a phase II dose during a phase I gene therapy study, the aim should be to identify the dose that can achieve the maximum biologic effect, which can occasionally reach a plateau at doses below the maximum tolerated dose. In gene transfer trials, it is essential that meaningful correlative endpoints are employed in order to correlate the employed doses with biological effect and select the most appropriate dose for phase II setting. This usually requires repeat tumor biopsies, a task not always easy when performed in a multicenter setting or for deep-seated tumors. It is found that despite systematic efforts in most gene therapy trials to assess the distribution of viral vectors/transgenes by performing repeat tissue biopsies, the results are often suboptimal. It is suggested to characterize the immune response against the vector and/or transgene if applicable, which certainly can affect the effectiveness of treatment, especially after systemic administration of the viral agent.

Original languageEnglish (US)
Title of host publicationNovel Anticancer Agents
PublisherElsevier Inc.
Pages379-390
Number of pages12
ISBN (Print)9780120885619
DOIs
StatePublished - 2006

Fingerprint

Gene therapy
Neoplasm Genes
Genetic Therapy
Clinical Trials
Gene transfer
Biopsy
Transgenes
Tumors
Genes
Maximum Tolerated Dose
Neoplasms
Cells
Tissue

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Cancer Gene Therapy Clinical Trials. From the Bench to the Clinic. / Galanis, Evanthia.

Novel Anticancer Agents. Elsevier Inc., 2006. p. 379-390.

Research output: Chapter in Book/Report/Conference proceedingChapter

Galanis, Evanthia. / Cancer Gene Therapy Clinical Trials. From the Bench to the Clinic. Novel Anticancer Agents. Elsevier Inc., 2006. pp. 379-390
@inbook{c68f414c4a5b4c45a4663e5fb08e8cb3,
title = "Cancer Gene Therapy Clinical Trials. From the Bench to the Clinic",
abstract = "This chapter focuses on some of the most important considerations in the design of gene therapy trials. Gene therapy is a medical intervention based on the introduction of genetic material in human cells in vivo or in vitro. Preclinical studies in support of use of gene transfer vector in clinical studies should be conducted in compliance with the regulations for good laboratory practice. It is suggested that when determining a phase II dose during a phase I gene therapy study, the aim should be to identify the dose that can achieve the maximum biologic effect, which can occasionally reach a plateau at doses below the maximum tolerated dose. In gene transfer trials, it is essential that meaningful correlative endpoints are employed in order to correlate the employed doses with biological effect and select the most appropriate dose for phase II setting. This usually requires repeat tumor biopsies, a task not always easy when performed in a multicenter setting or for deep-seated tumors. It is found that despite systematic efforts in most gene therapy trials to assess the distribution of viral vectors/transgenes by performing repeat tissue biopsies, the results are often suboptimal. It is suggested to characterize the immune response against the vector and/or transgene if applicable, which certainly can affect the effectiveness of treatment, especially after systemic administration of the viral agent.",
author = "Evanthia Galanis",
year = "2006",
doi = "10.1016/B978-012088561-9/50017-X",
language = "English (US)",
isbn = "9780120885619",
pages = "379--390",
booktitle = "Novel Anticancer Agents",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Cancer Gene Therapy Clinical Trials. From the Bench to the Clinic

AU - Galanis, Evanthia

PY - 2006

Y1 - 2006

N2 - This chapter focuses on some of the most important considerations in the design of gene therapy trials. Gene therapy is a medical intervention based on the introduction of genetic material in human cells in vivo or in vitro. Preclinical studies in support of use of gene transfer vector in clinical studies should be conducted in compliance with the regulations for good laboratory practice. It is suggested that when determining a phase II dose during a phase I gene therapy study, the aim should be to identify the dose that can achieve the maximum biologic effect, which can occasionally reach a plateau at doses below the maximum tolerated dose. In gene transfer trials, it is essential that meaningful correlative endpoints are employed in order to correlate the employed doses with biological effect and select the most appropriate dose for phase II setting. This usually requires repeat tumor biopsies, a task not always easy when performed in a multicenter setting or for deep-seated tumors. It is found that despite systematic efforts in most gene therapy trials to assess the distribution of viral vectors/transgenes by performing repeat tissue biopsies, the results are often suboptimal. It is suggested to characterize the immune response against the vector and/or transgene if applicable, which certainly can affect the effectiveness of treatment, especially after systemic administration of the viral agent.

AB - This chapter focuses on some of the most important considerations in the design of gene therapy trials. Gene therapy is a medical intervention based on the introduction of genetic material in human cells in vivo or in vitro. Preclinical studies in support of use of gene transfer vector in clinical studies should be conducted in compliance with the regulations for good laboratory practice. It is suggested that when determining a phase II dose during a phase I gene therapy study, the aim should be to identify the dose that can achieve the maximum biologic effect, which can occasionally reach a plateau at doses below the maximum tolerated dose. In gene transfer trials, it is essential that meaningful correlative endpoints are employed in order to correlate the employed doses with biological effect and select the most appropriate dose for phase II setting. This usually requires repeat tumor biopsies, a task not always easy when performed in a multicenter setting or for deep-seated tumors. It is found that despite systematic efforts in most gene therapy trials to assess the distribution of viral vectors/transgenes by performing repeat tissue biopsies, the results are often suboptimal. It is suggested to characterize the immune response against the vector and/or transgene if applicable, which certainly can affect the effectiveness of treatment, especially after systemic administration of the viral agent.

UR - http://www.scopus.com/inward/record.url?scp=84882511469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882511469&partnerID=8YFLogxK

U2 - 10.1016/B978-012088561-9/50017-X

DO - 10.1016/B978-012088561-9/50017-X

M3 - Chapter

AN - SCOPUS:84882511469

SN - 9780120885619

SP - 379

EP - 390

BT - Novel Anticancer Agents

PB - Elsevier Inc.

ER -